Finch, Takeda to Jointly Develop Microbiome Therapeutic for Ulcerative Colitis
News
Japan’s Takeda Pharmaceutical and Boston-based Finch Therapeutics will jointly develop the drug FIN-524 to treat ulcerative colitis, a form of inflammatory bowel disease (IBD). FIN-524 is Finch’s first microbiotic product candidate. The company says its live biotherapeutic product ... Read more